Quote:
"OK, I'd go for a 50/50 merger. Our IP with Biogen's pocketbook."
Xena and Nidan perhaps Dr. Missling has a mechanism in place where the "partnership", were one to occur, hinges on the announcement of all three of the trial starting. He would thereby guarantee by controlling the fact that the drug actually starts the trials, setting the wheels for approval in motion. By doing so he hasnt tied up resources or dilution to start something we are capable of. This would also maximize our leverage by start three precision medicine on the heels of possible approval with stellar results at 6 months. We should remember that Rett is an orphan drug designation, the FDA may feel that at 14 weeks of good results and safety in the bag, with nothing else remotely working, it may be forced to approve the drug.
I say the partnerships are being hammered out now as these trials may be quick in comparison to the old Goliath's.
Tred
News 
Market Data 
Discover 
